BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 26732315)

  • 1. Does Increased Spending on Pharmaceutical Marketing Inhibit Pioneering Innovation?
    Arnold DG; Troyer JL
    J Health Polit Policy Law; 2016 Apr; 41(2):157-79. PubMed ID: 26732315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reconciling Estimates of the Value to Firms of Reduced Regulatory Delay in the Marketing of Their New Drugs.
    Wilmoth DR
    Health Econ; 2015 Dec; 24(12):1651-6. PubMed ID: 25753390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The patents-based pharmaceutical development process: rationale, problems, and potential reforms.
    Barton JH; Emanuel EJ
    JAMA; 2005 Oct; 294(16):2075-82. PubMed ID: 16249422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of pharmaceuticals: ensuring the future of research and development.
    Serajuddin HK; Serajuddin AT
    J Am Pharm Assoc (2003); 2006; 46(4):511-6. PubMed ID: 16913396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Security market reaction to FDA fast track designations.
    Anderson CW; Zhang Y
    J Health Care Finance; 2010; 37(2):27-48. PubMed ID: 21294437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmaceutical research and development and the patent system.
    Love J
    Int J Health Serv; 2005; 35(2):257-63. PubMed ID: 15932006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Private versus social incentives for pharmaceutical innovation.
    González P; Macho-Stadler I; Pérez-Castrillo D
    J Health Econ; 2016 Dec; 50():286-297. PubMed ID: 26944633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Public policy and pharmaceutical innovation.
    Grabowski HG
    Health Care Financ Rev; 1982 Sep; 4(1):75-87. PubMed ID: 10309721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The price of innovation: new estimates of drug development costs.
    DiMasi JA; Hansen RW; Grabowski HG
    J Health Econ; 2003 Mar; 22(2):151-85. PubMed ID: 12606142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The changing environment for technological innovation in health care.
    Goodman CS; Gelijns AC
    Baxter Health Policy Rev; 1996; 2():267-315. PubMed ID: 11066263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methuselah's medicine: pharmaceutical innovation and mortality in the United States, 1960-2000.
    Schnittker J; Karandinos G
    Soc Sci Med; 2010 Apr; 70(7):961-8. PubMed ID: 20100632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Collaboration with universities and innovate activity in the Spanish pharmaceutical industry (2003-2005)].
    D'Este P; Tribó JA; García-Romero A
    Med Clin (Barc); 2008 Dec; 131 Suppl 5():66-70. PubMed ID: 19631826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revitalizing the patent system to incentivize pharmaceutical innovation: the potential of claims with means-plus-function clauses.
    Tang WL
    Duke Law J; 2013 Feb; 62(5):1069-108. PubMed ID: 25330553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The biotech drug market.
    Lawrence S
    Nat Biotechnol; 2004 Dec; 22(12):1496. PubMed ID: 15583645
    [No Abstract]   [Full Text] [Related]  

  • 16. Intended and unintended consequences of the gabapentin off-label marketing lawsuit among patients with bipolar disorder.
    Chace MJ; Zhang F; Fullerton CA; Huskamp HA; Gilden D; Soumerai SB
    J Clin Psychiatry; 2012 Nov; 73(11):1388-94. PubMed ID: 23146199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of external innovation on new drug approvals: A retrospective analysis.
    Liu X; Thomas CE; Felder CC
    Int J Pharm; 2019 May; 563():273-281. PubMed ID: 30664998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Funding pharmaceutical innovation through direct tax credits.
    Lybecker KM; Freeman RA
    Health Econ Policy Law; 2007 Jul; 2(Pt 3):267-84. PubMed ID: 18634650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Realizing two-tiered innovation policy through drug regulation.
    Ridgway WE
    Stanford Law Rev; 2006 Feb; 58(4):1221-50. PubMed ID: 16685807
    [No Abstract]   [Full Text] [Related]  

  • 20. Health care reform and the pharmaceutical industry.
    Mossinghoff GJ
    Health Care Manag; 1994 Aug; 1(1):187-96. PubMed ID: 10152353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.